CAPTRUST Financial Advisors
RNAM

CAPTRUST Financial Advisors’s Avidity Biosciences RNAM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-194
Closed -$3K – 3636
2022
Q2 		$3K Hold
194
– – ﹤0.01% 4336
2022
Q1 		$4K Sell
194
-195
-50% -$3.31K ﹤0.01% 4271
2021
Q4 		$9K Hold
389
– – ﹤0.01% 3789
2021
Q3 		$10K Buy
389
+195
+101% +$4.24K ﹤0.01% 3617
2021
Q2 		$5K Buy
+194
New +$4.51K ﹤0.01% 3874

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CAPTRUST Financial Advisors's RNAM Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Avidity Biosciences (RNAM) in Q3 2022, closing a stake of 194 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in RNAM in Q2 2021 and held it in 5 quarters. The position peaked at $10K in Q3 2021. 127 funds tracked by Wall St. Rank hold RNAM as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Avidity Biosciences position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 194 Avidity Biosciences shares in Q3 2022, an estimated $3K.
  • CAPTRUST Financial Advisors first reported a position in Avidity Biosciences in Q2 2021 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's Avidity Biosciences position peaked at $10K in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.